Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Total Current Liabilities
All obligations due within one year.
Galectin Therapeutics Inc.NASDAQ: GALT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 93.4% from a year ago
Total current liabilities stood at $7.31M at the end of Q1 FY2026, down 93.4% from a year earlier and down 9.0% from the prior quarter. Over 3 fiscal years it compounded at -14.9% a year.
Context
- Total current liabilities amounted to 46.4% of total assets at the end of Q1 FY2026, down 1116.9 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -93.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.03M USD
- Year-over-year change
- -77.3%
- 4-year CAGR
- -2.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.03M | -77.3% |
| FY2024 | 2024-12-31 | 35.41M | +125.9% |
| FY2023 | 2023-12-31 | 15.68M | +20.5% |
| FY2022 | 2022-12-31 | 13.01M | +44.0% |
| FY2021 | 2021-12-31 | 9.03M | — |
Total Current Liabilities vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's Mar 2026 total current liabilities of $7.31M is the 9th highest of the 10 companies compared; the peer median is $10.91M.
- Its year-over-year change of -93.4% is the lowest of 10, against a peer median of +19.4%.
- Total current liabilities amounts to 46.4% of total assets for GALT, versus a peer median of 7.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.47M | -30.7% | -8.3% | 8.6% | |
ENGNenGene Holdings Inc. | Apr 2026 | $21.49M | +19.4% | +229.6% | 7.0% |
| Mar 2026 | $16.71M | +37.4% | +20.7% | 12.1% | |
| Mar 2026 | $11.32M | +15.6% | -4.2% | 3.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M | +179.2% | +151.3% | 2.8% |
| Mar 2026 | $10.71M | -14.8% | +13.6% | 5.0% | |
| Mar 2026 | $10.45M | +7.0% | +34.3% | 9.6% | |
| Mar 2026 | $10.19M | +23.7% | +6.6% | 4.4% | |
| Mar 2026 | $7.31M | -93.4% | -14.9% | 46.4% | |
| Mar 2026 | $5.75M | +23.2% | +33.3% | 10.8% | |
| Peer median (excluding GALT) | $10.91M | +19.4% | +20.7% | 7.0% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 39.65M | 18.59M | 25.66M | 15.12M | 17.72M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.17M | 1.96M | 2.05M | 2.13M | 1.72M |
| Total Current Assets | 41.82M | 20.55M | 27.71M | 17.25M | 19.44M |
| Property, Plant & Equipment (Net) | 0 | 0 | 53K | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7K | 733K | 437K | 243K | 96K |
| Total Non-current Assets | 7K | 733K | 490K | 243K | 96K |
| Total Assets | 41.83M | 21.29M | 28.2M | 17.5M | 19.53M |
| Account Payables | 1.81M | 3.89M | 6.43M | 5.66M | 3.25M |
| Short-term Debt | 0 | 0 | 0 | 21.12M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.49M | 8.11M | 8.07M | 1.89M | 1.06M |
| Total Current Liabilities | 9.03M | 13.01M | 15.68M | 35.41M | 8.03M |
| Long-term Debt | 29.05M | 39.83M | 71.74M | 85.11M | 133.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.13M | 639K | 1M | 47K | 3.96M |
| Total Non-current Liabilities | 30.18M | 40.47M | 72.77M | 85.16M | 137.7M |
| Total Liabilities | 39.21M | 53.48M | 88.44M | 120.57M | 145.73M |
| Common Stock | 59K | 59K | 61K | 62K | 65K |
| Retained Earnings | (270.69M) | (309.57M) | (354.37M) | (401.57M) | (432.55M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 2.62M | (32.19M) | (60.24M) | (103.07M) | (126.2M) |
| Total Debt | 29.06M | 39.87M | 71.81M | 106.25M | 133.76M |
| Net Debt | (10.59M) | 21.28M | 46.15M | 91.13M | 116.04M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.